Recombinant Human Interleukin-7 (CYT107) to Promote T-Cell Recovery After Cord Blood Transplantation
Status: Withdrawn prior to enrolment
Phase of Trial: Phase I/II
Latest Information Update: 17 Jan 2019
Price : $35 *
At a glance
- Drugs Interleukin-7 (Primary)
- Indications Graft-versus-host disease
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- 08 Jan 2019 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 10 Sep 2018 Planned End Date changed from 1 Aug 2024 to 1 Nov 2024.
- 10 Sep 2018 Planned primary completion date changed from 1 Aug 2023 to 1 Nov 2023.